Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
39-amino-acid triple receptor agonist (GIP/GLP-1/glucagon) studied in cutting-edge metabolic-receptor research
Combining the powerful weight loss benefits of Semaglutide with the energy-boosting and metabolic support of Glycine and B12, this treatment offers a unique approach to shedding unwanted pounds effectively and sustainably
Decreased weight loss Contrave is approved for weight loss when taken with a reduced-calorie diet and increased physical activity
Our trained providers at Epiphany MedSpa can guide you on the best injection sites for optimal absorption and comfort
Mounjaro (tirzepatide) Disease area(s): Metabolic diseases Manufacturer(s): Eli Lilly and Company 2024 Sales (USD): $11.54 billion Why it sold so well: Eli Lillys dual GIP and GLP-1 receptor agonist for type 2 diabetes, Mounjaro, experienced exceptional growth in 2024, with global sales more than doubling to $11.54 billion
